3-(Piperidine-1-carbonyl)-5,11-dihydrobenzo[b][1,4]benzodiazepin-6-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: 3-(Piperidine-1-carbonyl)-5,11-dihydrobenzo[b][1,4]benzodiazepin-6-one
• 化学式: C₁₉H₁₉N₃O₂
• 分子量: 321.4
• InChiKey: QMDQOSQCWIWQGD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  24
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  61.4
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• [EN] MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR TREATING PANCREATITIS, GLIOBLASTOMA, SARCOPENIA AND STROKE<br/>[FR] MODULATEURS DE RÉCEPTEURS NUCLÉAIRES ORPHELINS DESTINÉS À TRAITER LA PANCRÉATITE, LE GLIOBLASTOME, LA SARCOPÉNIE ET UN ACCIDENT VASCULAIRE CÉRÉBRAL
  申请人：UNIV EMORY

  公开号：WO2022094435A1

  公开（公告）日：2022-05-05

  Compounds, compositions and methods for modulating retinoic acid receptor-like orphan receptors (ROR) so as to increase FGF21 levels, and treating and preventing disorders associated with FGF21, such as pancreatitis, sarcopenia, stroke, and traumatic brain injury, and to increase miR-122 levels, and treating and preventing disorders such as glioblastoma.

  化合物、组合物和方法，用于调节视黄酸受体样孤儿受体（ROR），以增加FGF21水平，并治疗和预防与FGF21相关的疾病，如胰腺炎、肌肉萎缩、中风和创伤性脑损伤，并增加miR-122水平，并治疗和预防胶质母细胞瘤等疾病。
• MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR NASH AND OTHER METABOLIC DISORDERS
  申请人：Emory University

  公开号：US20210052603A1

  公开（公告）日：2021-02-25

  Compounds, compositions and methods for modulating retinoic acid receptor-like orphan receptors (ROR) and associated diseases. Methods for treatment or prophylaxis of metabolic disorders, liver disorders or diseases, including NASH, immune disorders, central nervous system disorders, or cancer are disclosed.
• [EN] COMPOSITIONS AND METHODS FOR MODULATING POLY (ADP-RIBOSE) POLYMERASE ACTIVITY<br/>[FR] COMPOSITIONS ET PROCÉDÉS DE MODULATION DE L'ACTIVITÉ DE LA POLY(ADP-RIBOSE) POLYMÉRASE
  申请人：GEN HOSPITAL CORP

  公开号：WO2007056388A9

  公开（公告）日：2007-08-30

  [EN] The present invention is based, in part, on assays we conducted that revealed compounds that modulate (e.g., inhibit) PARP-1 and are therefore useful in treating or preventing diseases characterized by abnormal PARP-1 activity (e.g., undesirable PARP 1 activity).
  [FR] La présente invention est basée, en partie, sur des tests que nous avons menés qui ont révélé des composés qui modulent (par ex., inhibent) la PARP-1 et qui sont donc utiles dans le traitement ou la prévention de maladies caractérisées par une activité anormale de la PARP-1 (par ex., une activité de la PARP-1 indésirable).